Lars Endahl

3.1k total citations
32 papers, 2.4k citations indexed

About

Lars Endahl is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Lars Endahl has authored 32 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Lars Endahl's work include Diabetes Treatment and Management (27 papers), Diabetes Management and Research (24 papers) and Pancreatic function and diabetes (14 papers). Lars Endahl is often cited by papers focused on Diabetes Treatment and Management (27 papers), Diabetes Management and Research (24 papers) and Pancreatic function and diabetes (14 papers). Lars Endahl collaborates with scholars based in Denmark, United States and Canada. Lars Endahl's co-authors include Tim Heise, Leszek Nosek, Eberhard Draeger, Bernard Zinman, Chantal Mathieu, Christoph Kapitza, Lutz Heinemann, Birgitte Rønn, Stefano Del Prato and Thue Johansen and has published in prestigious journals such as The Lancet, Diabetes Care and Diabetes.

In The Last Decade

Lars Endahl

30 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Endahl Denmark	20	2.3k	1.3k	674	365	100	32	2.4k
Claresa Levetan United States	15	959 0.4×	326 0.3×	286 0.4×	161 0.4×	21 0.2×	25	1.2k
Kenneth E. Robertson United States	11	873 0.4×	259 0.2×	61 0.1×	457 1.3×	180 1.8×	14	1.0k
Bipin Sethi India	12	952 0.4×	313 0.2×	52 0.1×	485 1.3×	198 2.0×	44	1.2k
Joergen Rungby Denmark	10	577 0.3×	350 0.3×	44 0.1×	307 0.8×	98 1.0×	11	802
Ee Lin Lim United Kingdom	7	449 0.2×	376 0.3×	77 0.1×	185 0.5×	80 0.8×	11	949
João Eduardo Nunes Salles Brazil	16	319 0.1×	393 0.3×	65 0.1×	272 0.7×	48 0.5×	39	937
Richard A. Dickey United States	9	592 0.3×	182 0.1×	59 0.1×	74 0.2×	58 0.6×	29	826
Boniface J. Lin Taiwan	17	369 0.2×	198 0.2×	142 0.2×	155 0.4×	21 0.2×	42	669
J. �stman Sweden	13	293 0.1×	203 0.2×	199 0.3×	74 0.2×	31 0.3×	19	529
Sri Prakash Mokshagundam United States	13	288 0.1×	128 0.1×	71 0.1×	135 0.4×	50 0.5×	28	597

Countries citing papers authored by Lars Endahl

Since Specialization

Citations

This map shows the geographic impact of Lars Endahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Endahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Endahl more than expected).

Fields of papers citing papers by Lars Endahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Endahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Endahl. The network helps show where Lars Endahl may publish in the future.

Co-authorship network of co-authors of Lars Endahl

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Endahl. A scholar is included among the top collaborators of Lars Endahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Endahl. Lars Endahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Friedrichsen, Martin, Lars Endahl, Frederik Flindt Kreiner, et al.. (2023). Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. Molecular Metabolism. 78. 101801–101801. 27 indexed citations

Wharton, Sean, Arne Astrup, Lars Endahl, et al.. (2021). Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. International Journal of Obesity. 45(5). 923–933. 41 indexed citations

Tronieri, Jena Shaw, Anthony N. Fabricatore, Thomas A. Wadden, et al.. (2020). Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial. Obesity Facts. 13(6). 572–583. 9 indexed citations

Helmark, Ida Carøe, et al.. (2018). Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events). Therapeutic Innovation & Regulatory Science. 53(2). 279–286. 1 indexed citations

Scholten, Bernt Johan von, Melanie J. Davies, Frederik Persson, et al.. (2017). Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. Journal of Diabetes and its Complications. 31(7). 1164–1168. 8 indexed citations

Kumar, Sudhesh, Hak Chul Jang, Nilgün Güvener Demirağ, et al.. (2016). Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study. Diabetic Medicine. 34(2). 180–188. 34 indexed citations

Rodbard, Helena W., et al.. (2014). PO343 TREATMENT INTENSIFICATION WITH IDEGASP BID VS IDEG OD PLUS IASP IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED, CONTROLLED PHASE 3 TRIAL. Diabetes Research and Clinical Practice. 106. S222–S223. 3 indexed citations

Onishi, Yukiko, Yasuhiro Ono, Rasmus Rabøl, Lars Endahl, & S. Nakamura. (2013). Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obesity and Metabolism. 15(9). 826–832. 80 indexed citations

Niskanen, Leo, Lawrence A. Leiter, Edward Franek, et al.. (2012). Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. European Journal of Endocrinology. 167(2). 287–294. 47 indexed citations

10.

Garber, Alan J., Allen B. King, Stefano Del Prato, et al.. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. 379(9825). 1498–1507. 265 indexed citations

11.

Zinman, Bernard, Athena Philis‐Tsimikas, Bertrand Cariou, et al.. (2012). Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes. Diabetes Care. 35(12). 2464–2471. 270 indexed citations

12.

Zinman, Bernard, Greg Fulcher, Paturi Vishnupriya Rao, et al.. (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet. 377(9769). 924–931. 101 indexed citations

13.

Birkeland, Kåre I., Philip Home, Ulrich Wendisch, et al.. (2011). Insulin Degludec in Type 1 Diabetes. Diabetes Care. 34(3). 661–665. 126 indexed citations

14.

Zinman, Bernard, Greg Fulcher, Nihal Thomas, et al.. (2010). Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine. Diabetes. 59. 5 indexed citations

15.

Danne, Thomas, Nicolin Datz, Lars Endahl, et al.. (2008). Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial*. Pediatric Diabetes. 9(6). 554–560. 46 indexed citations

16.

Hompesch, Marcus, Barbara Troupin, Tim Heise, et al.. (2006). Time‐action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups*. Diabetes Obesity and Metabolism. 8(5). 568–573. 28 indexed citations

17.

Klein, Oliver, Jan Lynge, Lars Endahl, et al.. (2006). Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obesity and Metabolism. 9(3). 290–299. 201 indexed citations

18.

Heise, Tim, Leszek Nosek, Birgitte Rønn, et al.. (2004). Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes. Diabetes. 53(6). 1614–1620. 471 indexed citations

19.

Tüchsen, Finn & Lars Endahl. (1999). Increasing inequality in ischaemic heart disease morbidity among employed men in Denmark 1981-1993: the need for a new preventive policy. International Journal of Epidemiology. 28(4). 640–644. 51 indexed citations

20.

Gotzsche, P. C, Michael Stormly Hansen, Michael Stoltenberg, et al.. (1996). Randomized, Placebo Controlled Trial of Withdrawal of Slow-acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis. Scandinavian Journal of Rheumatology. 25(4). 194–199. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact